CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $220.36M, lower than 95% of all stocks globally
- PositionOperating margin is -20069.1%, lower than 95% of its Biotechnology peers (median -34.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
220.36MUSDvs all stocks (USD)
Revenue (TTM)
32.72MUSDvs all stocks (USD)
Profit Margin
-166.96%vs Biotechnology peers
Beta
0.4830xvs all stocks
52-Week Change
16.46%vs all stocks
Market Capitalization
220.36MUSDvs all stocks (USD)
Enterprise Value
153.98MUSDvs all stocks (USD)
Forward P/E
-2.50xvs Biotechnology peers
Price to Sales (TTM)
6.66xvs Biotechnology peers
Price to Book (MRQ)
5.18xvs Biotechnology peers
Enterprise to Revenue
4.71xvs Biotechnology peers
Enterprise to EBITDA
-2.82xvs Biotechnology peers
Gross Margin
70.91%vs Biotechnology peers
Profit Margin
-166.96%vs Biotechnology peers
Return on Assets (TTM)
-43.02%vs Biotechnology peers
Return on Equity (TTM)
-161.12%vs Biotechnology peers
Revenue (TTM)
32.72MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.6070USDUpdated Jul 19, 2026Quarterly Revenue Growth
-87.30%vs Biotechnology peers
Gross Profit (TTM)
32.55MUSDvs all stocks (USD)
EBITDA (TTM)
-54.63MUSDvs all stocks (USD)
Net Income (TTM)
-54.89MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-87.33%vs Biotechnology peers
Operating Cash Flow (TTM)
-54.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.46MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
33.48MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
190.00KUSDFY2025 · Dec 31, 2025Gross Profit
33.29MUSDFY2025 · Dec 31, 2025Operating Income
-51.81MUSDvs all stocks (USD)
Pre-tax Income
-52.70MUSDFY2025 · Dec 31, 2025Net Income
-52.70MUSDFY2025 · Dec 31, 2025EBIT
-51.55MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-51.48MUSDFY2025 · Dec 31, 2025Research & Development
58.19MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
26.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.15MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-54.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
-54.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
34.69MUSDFY2025 · Dec 31, 2025Interest Paid
1.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
327.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.98MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.06MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-489.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-76.31MUSDFY2025 · Dec 31, 2025Sale of Investments
49.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.94MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
16.36MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
88.24MUSDFY2025 · Dec 31, 2025Shares Outstanding
58.63MSharesUpdated Jul 19, 2026Float Shares
32.76MSharesUpdated Jul 19, 2026Shares Short
2.22MSharesUpdated Jul 19, 2026Short Ratio
4.35daysvs all stocks
Short % of Shares Outstanding
6.04%vs all stocks
% Held by Insiders
24.57%vs all stocks
% Held by Institutions
41.78%vs all stocks
Total Cash (MRQ)
94.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.58USDUpdated Jul 19, 2026Total Debt (MRQ)
15.85MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3110xvs Biotechnology peers
Current Ratio (MRQ)
7.03xvs Biotechnology peers
Book Value per Share (MRQ)
0.7030USDUpdated Jul 19, 2026Total Assets
114.86MUSDvs all stocks (USD)
Total Current Assets
107.91MUSDFY2025 · Dec 31, 2025Total Liabilities
61.29MUSDFY2025 · Dec 31, 2025Total Non-current Assets
6.95MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
44.55MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
34.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
71.82MUSDFY2025 · Dec 31, 2025Accounts Receivable
95.00KUSDFY2025 · Dec 31, 2025Inventory
310.00KUSDFY2025 · Dec 31, 2025Accounts Payable
6.09MUSDFY2025 · Dec 31, 2025Short-term Debt
751.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
15.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
16.79MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-362.58MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
53.57MUSDvs all stocks (USD)
52-Week Low
2.20USDUpdated Jul 19, 202652-Week High
5.42USDUpdated Jul 19, 202652-Week Change
16.46%vs all stocks
Beta
0.4830xvs all stocks
50-Day MA
4.00USDUpdated Jul 19, 2026200-Day MA
4.10USDUpdated Jul 19, 2026Avg 10-Day Volume
211.91KSharesUpdated Jul 19, 2026Avg 30-Day Volume
421.55KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9500USDUpdated Jul 19, 2026Other Income / Expense
254.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -20069.1%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -200.691Industry median: -0.34Industry P5: -43.55Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -1.67
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 7.03Altman Z-Score: -2.50
Financial Health
Altman Z-Score -2.5: distress zoneCritical
Altman Z-Score: -2.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $220.36M, lower than 95% of all stocks globallySignificant
Market cap (USD): 220,361,031Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Protara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk